Anti-Mouse Siglec-2/CD22 Polyclonal Antibody (MB011014)

Name: Anti-Mouse Siglec-2/CD22 Polyclonal Antibody
Brand: abinScience
SKU: MB011014
Price: 96 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

MB011014

Species reactivity

Mouse

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Mouse CD22 (Val146-Glu343).

Target

B-cell receptor CD22 (B-lymphocyte cell adhesion molecule) (BL-CAM) (Sialic acid-binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD antigen CD22)

Purification

Purified by antigen affinity column.

Accession

P35329

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

B-cell receptor CD22 is a ~97 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa).

1. Kelm, S. et al. (1994) Current biology : CB 4, 965-72. PMID: 7533044

2. Nitschke, L. et al. (1997) Current biology : CB 7, 133-43. PMID: 9016707

Note

For research use only.

Images

References

Datasheet

Anti-Mouse Siglec-2/CD22 Polyclonal Antibody.pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Mouse Siglec-2/CD22 Polyclonal Antibody (MB011014)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us